Alvotech, a developer of biosimilar medicines, is expanding its partnership with Advanz Pharma to commercialize three new products in Europe — one of them a biosimilar of Kesimpta (ofatumumab), a drug used for treating multiple sclerosis (MS). Biosimilars are therapies that have no clinically meaningful differences…
partnership
In a new deal, TG Therapeutics will use MaxCyte’s engineering technology to develop and manufacture its off-the-shelf CAR T-cell therapy candidate azercabtagene zapreleucel — azer-cel for short — for adults with progressive forms of multiple sclerosis (MS). The experimental treatment is being advanced toward a Phase 1…
To support the wellness journeys of Canadians living with multiple sclerosis (MS), digital healthcare company Sesh is partnering with MS Canada to provide free, unlimited access to its online mental health platform. The partnership allows patients to participate in virtual therapist-led support groups, and kickstarts research efforts…
Calyx and Qynapse have joined forces to expand the use of artificial intelligence (AI)-based neuroimaging tools in clinical trials of treatment candidates for conditions affecting the central nervous system (CNS), or the brain and spinal cord. This is expected to help advance therapy development for multiple sclerosis…
Find Therapeutics and SATT Conectus have joined forces to develop a promising therapy for multiple sclerosis (MS) and optic neuritis based on a new class of compounds that shows the potential to regenerate myelin. Myelin is the fatty protective sheath around nerve fibers that’s progressively lost…
Biogen has entered a licensing agreement to develop and potentially commercialize MedRhythms‘ investigational music-based digital therapy, MR-004, designed to help make walking easier for people with multiple sclerosis (MS). The partnership combines Biogen’s leadership and expertise in MS with MedRhythms’ digital therapeutics platform that uses sensors, algorithms, and music…
A new collaboration between Arterys and Combinostics seeks to bring comprehensive artificial intelligence (AI) imaging solutions to the diagnosis and care of patients with multiple sclerosis (MS) and other neurological diseases. Under the partnership, Arterys will include Combinostics’ AI-powered cNeuro on its medical imaging cloud AI platform…
BurnAlong and the Shepherd Center, a leading rehabilitation hospital in the U.S., have established a partnership to bring tailored rehabilitation classes to people with multiple sclerosis (MS) and other neuromuscular diseases worldwide. The video classes, designed by clinicians, therapists, and wellness professionals at the Shepherd Center, based in Atlanta,…
When Jon Strum began his “RealTalk MS” podcast two years ago, he did not imagine he soon would have thousands of regular listeners in more than 60 countries. Now, Strum’s popular online audio series has a new partner: the National Multiple Sclerosis Society (NMSS). Strum uses his weekly…
Biogen and Skyhawk Therapeutics have created a strategic partnership that will allow both companies to use Skyhawk’s SkySTAR technology platform for the discovery of new small molecule treatments for neurological diseases, including multiple sclerosis and spinal muscular atrophy. Under the terms of the agreement, Biogen will be given…
The MS Focus: Multiple Sclerosis Foundation will be accepting applications through June for its Cooling Program, which provides cooling garments to multiple sclerosis patients whose condition has left them heat-sensitive. Although 60 to 80 percent of patients are heat-sensitive, there were no MS-specific cooling garments on the U.S. market until…
Novartis and Pear Therapeutics are joining forces to develop novel prescription digital therapeutics to treat patients with schizophrenia and multiple sclerosis (MS). Digital therapeutics are software applications designed to treat diseases and improve clinical outcomes for patients. Combining Novartis’ expertise in biomedical research and clinical development with Pear’s…